Opioid-use disorder (OUD), a risk factor and major contributor to opioid-related deaths, is often underdiagnosed and undertreated. Currently there are three FDA-approved pharmacologic treatments for OUD maintenance therapy: methadone, buprenorphine (with or without naloxone), and naltrexone. Despite definitive evidence that methadone and buprenorphine products are effective in the treatment of OUD, there are still considerable accessibility and availability barriers that patients face when seeking Medication Assisted Treatment (MAT). The EXtended-release naltrexone vs Buprenorphine/naloxone for Opioid Treatment (X:BOT) trial compared the efficacy and safety of XR-NTX and BUP-NX to induce and maintain a patient with OUD on MAT as well as reducing opioid overdoses, relapses, and cravings.
Guest Author: Jordan L. Wulz, PharmD, MPH, BC-ADM, CHC
Music by Good Talk
CVD Risk Scores - Are They Accurate?
Folic Acid: A Simple Answer to a Very Large Problem?
Dressed for Success? Professional Attire and Patient Perceptions
Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?
Intensive Antiplatelet Therapy - Is Extended Therapy Worth It?
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Anticoagulation Bridge Therapy - Risks and Benefits Examined
Fish Oil for Rheumatoid Arthritis
Home-Based Primary Care: Can We Take These Results to the Bank?
Community Health Workers to Improve Asthma Outcomes
Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.